Marker Therapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Marker Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $7.87. The average 1-year stock price forecast is 450.35% higher than the current stock price, while the lowest is $5.60 (+291.61%) and the highest is $10 (+599.30%).

Price Target: $7.87 (+450.35%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.60	$7.87	$8.00	$10
Change	+291.61%	+450.35%	+459.44%	+599.30%

Analyst Ratings

The average analyst rating for Marker Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Mar '26	May '26
Strong Buy	2	2	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Patrick Trucchio H.C. Wainwright	H.C. Wainwright	Buy Reiterates $10	Buy	Reiterates	$10	+599.30%	May 19, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Buy Maintains $8	Buy	Maintains	$8	+459.44%	May 19, 2026

Financial Forecast

Revenue This Year

2.83M

from 3.55M

-20.20%

from 3.55M

Revenue Next Year

20.09M

from 2.83M

609.66%

from 2.83M

EPS This Year

-0.55

from -0.76

EPS Next Year

-0.17

from -0.55

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.24M	3.51M	3.31M	6.59M	3.55M	2.83M
Revenue Growth	166.01%	182.96%	-5.76%	99.06%	-46.19%	-20.20%
Gross Profit	-26.55M	-8.45M	-7.11M	-6.88M	-8.25M	2.83M
Gross Margin	-2,138.44%	-240.64%	-214.60%	-104.33%	-232.68%	100.00%
Operating Income	-39.48M	-19.79M	-14.58M	-11.12M	-12.44M	-19.65M
Net Income	-41.88M	-29.93M	-8.24M	-10.73M	-12.16M	-19.36M
EPS	-	-	-	-	-0.76	-0.55
Free Cash Flow	-12.98M	-14.77M	-10.14M	-7.13M	-8.60M	-9.80M
No. Analysts	-	-	-	-	-	3

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	5.1M
Avg	2.8M
Low	800,000

Revenue Growth

Revenue Growth	2026	2027	2028
High	43.5%
Avg	-20.2%
Low	-77.4%

EPS Forecast

EPS	2026	2027	2028
High	-0.55
Avg	-0.55
Low	-0.55

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-